(Q35194527)

7 August 2017

1 reference

title

Safety evaluation of the drugs available to prevent malaria (English)

1 reference

7 August 2017

0 references

1 reference

1

Ashley M Croft

1 reference

7 August 2017

Dominic P Whitehouse

2

1 reference

7 August 2017

Gordon C Cook

series ordinal

3

1 reference

7 August 2017

M Dominic Beer

series ordinal

4

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Expert Opinion on Drug Safety

7 August 2017

published in

1 reference

7 August 2017

volume

1

1 reference

7 August 2017

issue

1

1 reference

7 August 2017

page(s)

19-27

1 reference

Resurgent malaria at the millennium: control strategies in crisis

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Antimalarial drug resistance: the pace quickens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Science commentary: protection against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

User Acceptability Patterns for Mefloquine and Doxycycline Malaria Chemoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Malaria among United States troops in Somalia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Doxycycline as first line malarial prophylaxis: how safe is it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

New aspects of malaria imported from Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Systematic review of amodiaquine treatment in uncomplicated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Mefloquine (WR 142,490) in the Treatment of Human Malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Suppressive activity of mefloquine in sporozoite-induced human malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Neurologic reactions after a therapeutic dose of mefloquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

CNS adverse events associated with antimalarial agents. Fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Malaria prophylaxis and the media.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Mefloquine to prevent malaria: a systematic review of trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Malaria chemoprophylaxis: why mefloquine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Long-term malaria prophylaxis with weekly mefloquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Evidence based patient information. is important, so there needs to be a national strategy to ensure it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Adverse events associated with mefloquine. Explaining about possible adverse events may reduce problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Confused malaria chemoprophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Time to put malaria control on the global agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Making malaria research bite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Systematic reviews: synthesis of best evidence for clinical decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

How to read a paper. Papers that report drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Interpretation in drug epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Statistical issues in pharmacoepidemiological case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Clinical guidelines: developing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Paternalism or partnership? Patients have grown up-and there's no going back

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Practice guidelines, a new reality in medicine. II. Methods of developing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Development and application of a generic methodology to assess the quality of clinical guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

Consumer participation in research and health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.19

21 January 2018

Identifiers

DOI

10.1517/14740338.1.1.19

1 reference

7 August 2017

1 reference